CARTISTEM^® – allogeneic umbilical cord blood-derived mesenchymal stem cells, is used for the treatment of knee cartilage defects in patients with Osteoarthritis (with ICRS grade* IV cartilage defect) caused by degeneration or repetitive trauma.

PNEUMOSTEM^® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is currently under development for the preventive treatment of Bronchopulmonary Dysplasia(BPD) in premature infants. Currently, Phase 2 clinical trial is ongoing in Korea and PNEUMOSTEM^® has been Orphan Drug designated by US FDA and EMA. Recently, US FDA granted a Fast Track Designation for PNEUMOSTEM^®.

NEUROSTEM^® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is under development for the treatment of Alzheimer’s Disease. Currently, NEUROSTEM^® is undergoing Phase 2a clinical trial after successfully completing the Phase 1 clinical trial in Korea.

SMUP-IA-01, SMUP allogeneic umbilical cord blood-derived mesenchymal stem cells, is currently under development for the treatment and prevention of Osteoarthritis. Currently, SMUP-IA-01 is undergoing Phase 1 clinical trial in Korea with IND from the MFDS.

SMUP-IV-01, an SMUP allogeneic umbilical cord blood-derived mesenchymal stem cels, is under development for the treatment and prevention of Diabetic Nephropathy. Currently, SMUP-IV-01 is in the process of applying for phase 1 clinical trial of the MFDS.